ImmunoScape raises $14M for its deep immunomics platform

By The Science Advisory Board staff writers

April 14, 2021 -- ImmunoScape has completed a financing round that raised $14 million to enlarge its Singapore-based team, further its expansion into the U.S., and scale up its new San Diego laboratory.

The company will also continue advancing the capabilities of its deep immunomics platform, which enables the characterization of a patient's immunome at ultrahigh resolution. The funds will support increasing the capacity for in-house research and development activities. ImmunoScape plans to expand its biopharmaceutical and academic partnerships in drug development efforts within immuno-oncology, infectious diseases, and autoimmune diseases.

The deep immunomics platform integrates single-cell analysis technologies and bioinformatics for both drug discovery and high-dimensional immune profiling.

This financing round was led by existing investors Anzu Partners, University of Tokyo Edge Capital Partners (UTEC), and new investor EDBI, an investment arm of the Economic Development Board of Singapore. In the past year, ImmunoScape has raised a total of $25 million.

Valo, ImmunoScape partner on pancoronavirus vaccine
Valo Therapeutics has completed a collaboration with ImmunoScape to identify immunogenic peptides for the development of a pancoronavirus vaccine.
ImmunoScape raises $11M to develop COVID-19 therapies
ImmunoScape has raised $11 million in financing to research how T-cell immune response contributes to COVID-19 immunity, with the goal of aiding...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter